Synergy Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 93   

Articles published

SGYP 6.39 +0.22 (3.57%)
price chart
Could Synergy Pharmaceuticals Inc Change Direction After Today's Huge Increase?
The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) is a huge mover today! The stock increased 3.57% or $0.22 during the last trading session, hitting $6.39.
Synergy Pharmaceuticals Stock Price Up 3.2% (SGYP)  Putnam Standard
Closing Bell Reports: Synergy Pharmaceuticals, Inc. (SGYP), KB Home (KBH ...  WallStreet Scope
Analysts Bullish on Synergy Pharmaceuticals Inc. (SGYP) and Zogenix, Inc ...
Analysts weigh in with a few insights on biopharmaceutical companies Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) and Zogenix, Inc. (NASDAQ:ZGNX), following the release of their quarterly results this week.
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) Short Interest Update  Money Flow Index
Synergy Pharmaceuticals Stock Rating Upgraded by Vetr Inc. (SGYP)  Dakota Financial News
Synergy Pharmaceuticals, Inc. Short Interest Update
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) has witnessed a drop of 2.6% or 740,302 shares in its short figure. The short interest diminution took it from 27,994,550 on October 30,2015 to 27,254,248 on November 13,2015.
Synergy Pharmaceuticals (SGYP) – Research Analysts' Recent Ratings Changes  Voice Chronicle
Will Synergy Pharmaceuticals DE (NASDAQ:SGYP) be able to hit Analyst ...  The Bulletin
Synergy Pharmaceuticals Inc's (SGYP) Plecanatide Still Big Opportunity: Canaccord
In a research report released this morning, Canaccord analyst Corey Davis reiterated a Buy rating on shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) with a price target of $19, which implies an upside of 208% from current levels. Davis wrote, “In ...
Synergy Pharmaceuticals Receives Buy Rating from Canaccord Genuity (SGYP)  The Market Business
Is Synergy Pharmaceuticals Inc (SGYP) A Good Stock To Buy?
Does Synergy Pharmaceuticals Inc (NASDAQ:SGYP) represent a good buying opportunity at the moment? Let's briefly check the hedge fund sentiment towards the company.
Company Shares of Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) Drops by -1.52%  American Trade Journal
Synergy Pharmaceuticals Given Average Rating of "Buy" by Analysts ...  Dakota Financial News
Synergy Pharmaceuticals Inc (SGYP)'s Plecanatide Stays Compelling Despite ...
In a research report released today, Rodman & Renshaw analyst Ram Selvaraju reiterated a Buy rating on shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP), with a price target of $20, after competitor Ironwood Pharmaceuticals reported positive data ...
Why Synergy Pharmaceuticals, Inc. Shares Are Surging Higher
However, before investors get too excited, they should remember that Synergy Pharmaceuticals is a clinical-stage company without any products on the market or revenue. Also, investors need to remember that there's no guarantee that an FDA approval ...
Why This Analyst Sees Synergy Pharma Still Doubling Even After Huge Gains  24/7 Wall St.
Analysts Positive on Synergy Pharmaceuticals Inc (SGYP) Following Positive ...  Smarter Analyst
Time To Buy Synergy Pharma, Roth Capital Says
The share price of Synergy Pharmaceuticals Inc (NASDAQ: SGYP) has appreciated by 88.35 percent over the last six months, from a low of $3.44 on May 5. Roth Capital's Michael Higgins has reinitiated coverage of the company with a Buy rating and price ...
Synergy Pharmaceuticals Receives Buy Rating from Roth Capital (SGYP)  Voice Chronicle
Synergy Pharmaceuticals Receives Consensus Rating of "Buy" from ...  Dakota Financial News
Synergy Pharmaceuticals: Major Upside Ahead
Synergy Pharmaceuticals (NASDAQ:SGYP) is a small biopharmaceutical company focused on the development of novel therapies for the treatment of gastrointestinal "GI" diseases and disorders.
Price Target Update on Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) should head towards $14.75 per share according to 2 Analysts in consensus.
Update: Analysts Rate Synergy Pharmaceuticals DE (NASDAQ:SGYP) a 1 on ...  The Bulletin